表紙
市場調査レポート

子宮体癌:パイプライン製品の分析

Endometrial Cancer - Pipeline Review, H1 2016

発行 Global Markets Direct 商品コード 229742
出版日 ページ情報 英文 345 Pages
即納可能
価格
本日の銀行送金レート: 1USD=102.12円で換算しております。
Back to Top
子宮体癌:パイプライン製品の分析 Endometrial Cancer - Pipeline Review, H1 2016
出版日: 2016年05月18日 ページ情報: 英文 345 Pages
概要

子宮体癌(子宮内膜癌)とは、子宮の内膜で発症する癌を指し、子宮癌の中でも最も一般的なものです。子宮体癌の実際の原因はまだ不明ですが、エストロゲンの数値上昇が何らかの役割を果たしていると見られています。というのも、エストロゲンは子宮内膜の発達を促進する働きがあるからです。主な症状として、不正出血(中間期出血や、閉経後の少量の出血を含む)や、40歳以降の膣出血(期間が極度に長く頻繁で症状が重いもの)、下腹部の痛み、骨盤のけいれん、閉経後の白色/透明の膣分泌物などが挙げられます。

当レポートでは、世界各国での子宮体癌(子宮内膜癌)治療用のパイプライン製品の開発状況について分析し、製品開発・上市の最新動向や、治験の各段階にある製品の一覧、主要企業のプロファイル、主な薬剤の概要、最新の業界動向などの情報をお届けします。

イントロダクション

  • 調査範囲

子宮体癌の概要

治療薬の開発

  • パイプライン製品の概要
  • パイプライン製品の比較分析

子宮体癌:企業で開発中の治療薬

子宮体癌:大学/機関で研究中の治療薬

子宮体癌:パイプライン製品の概況

  • 後期段階の製品
  • 臨床段階の製品
  • 初期段階の製品

子宮体癌:企業で開発中の製品

子宮体癌:大学/機関で研究中の製品

子宮体癌の治療薬開発に従事している企業

  • Ability Pharmaceuticals, S.L.
  • Advenchen Laboratories, LLC
  • Aeterna Zentaris Inc.
  • Arno Therapeutics, Inc.
  • ArQule, Inc.
  • AstraZeneca Plc
  • AVEO Pharmaceuticals, Inc.
  • BeiGene, Ltd.
  • BioNTech AG
  • Boehringer Ingelheim GmbH
  • Bristol-Myers Squibb Company
  • Cellceutix Corporation
  • Critical Outcome Technologies Inc.
  • エーザイ
  • Eli Lilly and Company
  • Esperance Pharmaceuticals, Inc.
  • Exelixis, Inc.
  • Galena Biopharma, Inc.
  • Genmab A/S
  • GlaxoSmithKline Plc
  • Gradalis Inc.
  • Horizon Pharma Plc
  • ImmunoGen, Inc.
  • Incyte Corporation
  • Karyopharm Therapeutics, Inc.
  • Medivation, Inc.
  • Merck & Co., Inc.
  • Merck KGaA
  • Millennium Pharmaceuticals, Inc.
  • Novartis AG
  • OncoHoldings, Inc.
  • 大塚ホールディングス
  • Pfizer Inc.
  • Pharma Mar, S.A.
  • Pharmsynthez
  • Pivot Pharmaceuticals Inc
  • Puma Biotechnology, Inc.
  • Sanofi
  • Shenogen Pharma Group Ltd.
  • Synthon Holdings BV
  • Vertex Pharmaceuticals Incorporated
  • Vyriad

子宮体癌:治療薬の評価

  • 単剤製品
  • 併用製品
  • 標的別
  • 作用機序別
  • 投与経路別
  • 分子タイプ別

薬剤プロファイル

子宮体癌:最近のパイプライン動向

子宮体癌:休止中のプロジェクト

子宮体癌:開発が中止された製品

子宮体癌:製品開発のマイルストーン

  • 主なニュースとプレスリリース

付録

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC8014IDB

Summary

Global Markets Direct's, 'Endometrial Cancer - Pipeline Review, H1 2016', provides an overview of the Endometrial Cancer pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Endometrial Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Endometrial Cancer and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Endometrial Cancer
  • The report reviews pipeline therapeutics for Endometrial Cancer by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Endometrial Cancer therapeutics and enlists all their major and minor projects
  • The report assesses Endometrial Cancer therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Endometrial Cancer

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Endometrial Cancer
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Endometrial Cancer pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Endometrial Cancer Overview
  • Therapeutics Development
    • Pipeline Products for Endometrial Cancer - Overview
    • Pipeline Products for Endometrial Cancer - Comparative Analysis
  • Endometrial Cancer - Therapeutics under Development by Companies
  • Endometrial Cancer - Therapeutics under Investigation by Universities/Institutes
  • Endometrial Cancer - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
  • Endometrial Cancer - Products under Development by Companies
  • Endometrial Cancer - Products under Investigation by Universities/Institutes
  • Endometrial Cancer - Companies Involved in Therapeutics Development
    • Ability Pharmaceuticals, S.L.
    • Advenchen Laboratories, LLC
    • Aeterna Zentaris Inc.
    • Arno Therapeutics, Inc.
    • ArQule, Inc.
    • AstraZeneca Plc
    • AVEO Pharmaceuticals, Inc.
    • BeiGene, Ltd.
    • BioNTech AG
    • Boehringer Ingelheim GmbH
    • Bristol-Myers Squibb Company
    • Cellceutix Corporation
    • Critical Outcome Technologies Inc.
    • Eisai Co., Ltd.
    • Eli Lilly and Company
    • Esperance Pharmaceuticals, Inc.
    • Exelixis, Inc.
    • Galena Biopharma, Inc.
    • Genmab A/S
    • GlaxoSmithKline Plc
    • Gradalis Inc.
    • Horizon Pharma Plc
    • ImmunoGen, Inc.
    • Incyte Corporation
    • Karyopharm Therapeutics, Inc.
    • Medivation, Inc.
    • Merck & Co., Inc.
    • Merck KGaA
    • Millennium Pharmaceuticals, Inc.
    • Novartis AG
    • OncoHoldings, Inc.
    • Otsuka Holdings Co., Ltd.
    • Pfizer Inc.
    • Pharma Mar, S.A.
    • Pharmsynthez
    • Pivot Pharmaceuticals Inc
    • Puma Biotechnology, Inc.
    • Sanofi
    • Shenogen Pharma Group Ltd.
    • Synthon Holdings BV
    • Vertex Pharmaceuticals Incorporated
    • Vyriad
  • Endometrial Cancer - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Combination Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • ²¹²Pb-TCMC-Trastuzumab - Drug Profile
    • ABTL-0812 - Drug Profile
    • AEZS-125 - Drug Profile
    • AL-3818 - Drug Profile
    • ARQ-092 - Drug Profile
    • AV-203 - Drug Profile
    • AZD-2014 - Drug Profile
    • AZD-5363 - Drug Profile
    • BGB-283 - Drug Profile
    • buparlisib hydrochloride - Drug Profile
    • cabozantinib s-malate - Drug Profile
    • Cellular Immunotherapy for Oncology - Drug Profile
    • Cellular Immunotherapy for Ovarian and Endometrial Cancer - Drug Profile
    • Cellular Immunotherapy to Taregt HER-2 for Oncology - Drug Profile
    • COTI-2 - Drug Profile
    • cridanimod - Drug Profile
    • DT-1154 - Drug Profile
    • EP-200 - Drug Profile
    • epacadostat - Drug Profile
    • everolimus - Drug Profile
    • GALE-301 - Drug Profile
    • gemogenovatucel-T - Drug Profile
    • GSK-2636771 - Drug Profile
    • HO-3867 - Drug Profile
    • INCB-50465 - Drug Profile
    • INCB-54828 - Drug Profile
    • interferon gamma-1b - Drug Profile
    • itacitinib adipate - Drug Profile
    • KM-3174 - Drug Profile
    • lenvatinib mesylate - Drug Profile
    • lurbinectedin - Drug Profile
    • LY-3023414 - Drug Profile
    • mirvetuximab soravtansine - Drug Profile
    • MK-2206 - Drug Profile
    • Monoclonal Antibody to Inhibit L1CAM for Ovarian and Endometrial Cancer - Drug Profile
    • neratinib - Drug Profile
    • nintedanib - Drug Profile
    • onapristone ER - Drug Profile
    • ONCO-101 - Drug Profile
    • Oncolytic Virus to Activate IFNb for Endometrial Cancer - Drug Profile
    • Oncolytic Virus to Target CD46 for Gynecological Cancers and Urinary Tract Cancer - Drug Profile
    • OPB-111001 - Drug Profile
    • Peptides to Inhibit GnRH II Receptor for Oncology - Drug Profile
    • PF-06671008 - Drug Profile
    • pimasertib hydrochloride + voxtalisib - Drug Profile
    • PVT-005 - Drug Profile
    • sapanisertib - Drug Profile
    • SAR-408701 - Drug Profile
    • selinexor - Drug Profile
    • sirolimus albumin-bound - Drug Profile
    • Small Molecules to Inhibit Skp2 for Endometrial Cancer and Melanoma - Drug Profile
    • SNG-1153 - Drug Profile
    • SP-2509 - Drug Profile
    • SYD-985 - Drug Profile
    • talazoparib - Drug Profile
    • tisotumab vedotin - Drug Profile
    • trametinib dimethyl sulfoxide + uprosertib - Drug Profile
    • uprosertib - Drug Profile
    • VX-984 - Drug Profile
    • X-480 - Drug Profile
    • zoptarelin doxorubicin - Drug Profile
  • Endometrial Cancer - Recent Pipeline Updates
  • Endometrial Cancer - Dormant Projects
  • Endometrial Cancer - Discontinued Products
  • Endometrial Cancer - Product Development Milestones
    • Featured News & Press Releases
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Endometrial Cancer, H1 2016
  • Number of Products under Development for Endometrial Cancer - Comparative Analysis, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Number of Products under Development by Companies, H1 2016 (Contd..1)
  • Number of Products under Development by Companies, H1 2016 (Contd..2)
  • Number of Products under Investigation by Universities/Institutes, H1 2016
  • Comparative Analysis by Late Stage Development, H1 2016
  • Comparative Analysis by Clinical Stage Development, H1 2016
  • Comparative Analysis by Early Stage Development, H1 2016
  • Products under Development by Companies, H1 2016
  • Products under Development by Companies, H1 2016 (Contd..1)
  • Products under Development by Companies, H1 2016 (Contd..2)
  • Products under Development by Companies, H1 2016 (Contd..3)
  • Products under Investigation by Universities/Institutes, H1 2016
  • Endometrial Cancer - Pipeline by Ability Pharmaceuticals, S.L., H1 2016
  • Endometrial Cancer - Pipeline by Advenchen Laboratories, LLC, H1 2016
  • Endometrial Cancer - Pipeline by Aeterna Zentaris Inc., H1 2016
  • Endometrial Cancer - Pipeline by Arno Therapeutics, Inc., H1 2016
  • Endometrial Cancer - Pipeline by ArQule, Inc., H1 2016
  • Endometrial Cancer - Pipeline by AstraZeneca Plc, H1 2016
  • Endometrial Cancer - Pipeline by AVEO Pharmaceuticals, Inc., H1 2016
  • Endometrial Cancer - Pipeline by BeiGene, Ltd., H1 2016
  • Endometrial Cancer - Pipeline by BioNTech AG, H1 2016
  • Endometrial Cancer - Pipeline by Boehringer Ingelheim GmbH, H1 2016
  • Endometrial Cancer - Pipeline by Bristol-Myers Squibb Company, H1 2016
  • Endometrial Cancer - Pipeline by Cellceutix Corporation, H1 2016
  • Endometrial Cancer - Pipeline by Critical Outcome Technologies Inc., H1 2016
  • Endometrial Cancer - Pipeline by Eisai Co., Ltd., H1 2016
  • Endometrial Cancer - Pipeline by Eli Lilly and Company, H1 2016
  • Endometrial Cancer - Pipeline by Esperance Pharmaceuticals, Inc., H1 2016
  • Endometrial Cancer - Pipeline by Exelixis, Inc., H1 2016
  • Endometrial Cancer - Pipeline by Galena Biopharma, Inc., H1 2016
  • Endometrial Cancer - Pipeline by Genmab A/S, H1 2016
  • Endometrial Cancer - Pipeline by GlaxoSmithKline Plc, H1 2016
  • Endometrial Cancer - Pipeline by Gradalis Inc., H1 2016
  • Endometrial Cancer - Pipeline by Horizon Pharma Plc, H1 2016
  • Endometrial Cancer - Pipeline by ImmunoGen, Inc., H1 2016
  • Endometrial Cancer - Pipeline by Incyte Corporation, H1 2016
  • Endometrial Cancer - Pipeline by Karyopharm Therapeutics, Inc., H1 2016
  • Endometrial Cancer - Pipeline by Medivation, Inc., H1 2016
  • Endometrial Cancer - Pipeline by Merck & Co., Inc., H1 2016
  • Endometrial Cancer - Pipeline by Merck KGaA, H1 2016
  • Endometrial Cancer - Pipeline by Millennium Pharmaceuticals, Inc., H1 2016
  • Endometrial Cancer - Pipeline by Novartis AG, H1 2016
  • Endometrial Cancer - Pipeline by OncoHoldings, Inc., H1 2016
  • Endometrial Cancer - Pipeline by Otsuka Holdings Co., Ltd., H1 2016
  • Endometrial Cancer - Pipeline by Pfizer Inc., H1 2016
  • Endometrial Cancer - Pipeline by Pharma Mar, S.A., H1 2016
  • Endometrial Cancer - Pipeline by Pharmsynthez, H1 2016
  • Endometrial Cancer - Pipeline by Pivot Pharmaceuticals Inc, H1 2016
  • Endometrial Cancer - Pipeline by Puma Biotechnology, Inc., H1 2016
  • Endometrial Cancer - Pipeline by Sanofi, H1 2016
  • Endometrial Cancer - Pipeline by Shenogen Pharma Group Ltd., H1 2016
  • Endometrial Cancer - Pipeline by Synthon Holdings BV, H1 2016
  • Endometrial Cancer - Pipeline by Vertex Pharmaceuticals Incorporated, H1 2016
  • Endometrial Cancer - Pipeline by Vyriad, H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Assessment by Combination Products, H1 2016
  • Number of Products by Stage and Target, H1 2016
  • Number of Products by Stage and Mechanism of Action, H1 2016
  • Number of Products by Stage and Route of Administration, H1 2016
  • Number of Products by Stage and Molecule Type, H1 2016
  • Endometrial Cancer Therapeutics - Recent Pipeline Updates, H1 2016
  • Endometrial Cancer - Dormant Projects, H1 2016
  • Endometrial Cancer - Dormant Projects (Contd..1), H1 2016
  • Endometrial Cancer - Dormant Projects (Contd..2), H1 2016
  • Endometrial Cancer - Discontinued Products, H1 2016

List of Figures

  • Number of Products under Development for Endometrial Cancer, H1 2016
  • Number of Products under Development for Endometrial Cancer - Comparative Analysis, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Number of Products under Investigation by Universities/Institutes, H1 2016
  • Comparative Analysis by Clinical Stage Development, H1 2016
  • Comparative Analysis by Early Stage Products, H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Assessment by Combination Products, H1 2016
  • Number of Products by Top 10 Targets, H1 2016
  • Number of Products by Stage and Top 10 Targets, H1 2016
  • Number of Products by Top 10 Mechanism of Actions, H1 2016
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016
  • Number of Products by Top 10 Routes of Administration, H1 2016
  • Number of Products by Stage and Top 10 Routes of Administration, H1 2016
  • Number of Products by Top 10 Molecule Types, H1 2016
  • Number of Products by Stage and Top 10 Molecule Types, H1 2016
Back to Top